Daré Bioscience, Inc.
DARE
$2.04
-$0.04-1.92%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Net Income | -131.11% | 35.19% | -8.87% | 43.34% | 247.35% |
Total Depreciation and Amortization | 2,887.66% | 1,363.89% | -36.00% | 4.30% | 60.42% |
Total Amortization of Deferred Charges | -127.83% | 2,400.00% | -- | -- | -- |
Total Other Non-Cash Items | -16.19% | -65.88% | 249.05% | -6.06% | -0.19% |
Change in Net Operating Assets | -216.11% | -17.11% | 478.74% | -363.16% | -154.99% |
Cash from Operations | -141.98% | 19.70% | 163.90% | 25.71% | 295.93% |
Capital Expenditure | 153.79% | -2,054.79% | 7.33% | 1,377.38% | -- |
Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
Cash Acquisitions | -- | -- | -- | -- | -- |
Divestitures | -- | -- | -- | -- | -- |
Other Investing Activities | -- | -- | -- | -- | -- |
Cash from Investing | 153.79% | -2,054.79% | 7.33% | 1,377.38% | -- |
Total Debt Issued | -- | -- | -- | -6.57% | -- |
Total Debt Repaid | -680.39% | 6.59% | 6.59% | 6.59% | -- |
Issuance of Common Stock | 159.56% | 102.79% | -92.94% | -100.00% | -59.53% |
Repurchase of Common Stock | -- | -- | -- | -- | -- |
Issuance of Preferred Stock | -- | -- | -- | -- | -- |
Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
Total Dividends Paid | -- | -- | -- | -- | -- |
Other Financing Activities | 412.50% | -257.14% | -100.01% | -- | -- |
Cash from Financing | -137.95% | 1,661.43% | -102.49% | -94.91% | -74.48% |
Foreign Exchange rate Adjustments | -11.64% | 133.42% | -212.97% | 252.67% | 146.79% |
Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
Net Change in Cash | -141.53% | 21.58% | 230.63% | -1,016.75% | 306.79% |